Historic Time in Treatment of Rare Disease as Promising Drugs Reach Phase 3 Trials
Site Search
Showing 31 - 40 of 268 results
News
|
|
2 min read
News
|
|
2 min read
Press Release
|
|
3 min read
This month, 15-year-old Molly Bonnell and her sister Emily, 13, who have cystic fibrosis, discovered how easy it is to make their voices heard in Congress -- without leaving their living room.
News
|
|
2 min read
News
|
|
2 min read
News
|
|
2 min read
News
|
|
1 min read
Legislation to Help Speed Research for Cystic Fibrosis and Other Rare Diseases
Press Release
|
|
4 min read
The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.
News
|
|
3 min read
Tezacaftor/ivacaftor (Symdeko™) is approved for individuals with two copies of the most common cystic fibrosis mutation, F508del, as well as for individuals who have a single copy of one of 26 specified mutations -- regardless of their other mutation.
News
|
|
4 min read